Drug licensing deal brings millions in Israeli capital to Burnaby

Israel’s Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has announced that it will pay Burnaby-based Xenon Pharmaceuticals Inc. up to $376 million for a worldwide license to ...

Israel’s Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has announced that it will pay Burnaby-based Xenon Pharmaceuticals Inc. up to $376 million for a worldwide license to a pain drug that Xenon is developing.

The deal will see Teva pay Xenon $41 million up front, and then fund up to $335 million in “development, regulatory and sales-based milestones” for Xenon’s drug, XEN402. For its investment, Teva will obtain an exclusive worldwide license for the drug. Xenon will be entitled to royalties payable on sales and an option to participate in commercialization in the U.S.

Jeremy Levin, president and CEO of Teva, welcomed the deal.

“[This drug] holds the potential to address the significant unmet medical need for the many patients who suffer from chronic pain,” he said. “In addition, XEN402 has the potential for broader therapeutic use across other pain conditions.”

Simon Pimstone, president and CEO of Xenon, also expressed satisfaction with the deal.

“This partnership with Teva,” he said, “is Xenon’s seventh major pharmaceutical alliance, once again highlighting the value of Xenon’s unique genetics approach and translational R&D capabilities.”

The drug is currently in clinical development.

jwagler@biv.com

@JennyWagler_BIV

comments powered by Disqus

Also Read

More From Innovation

Tyler Orton discusses Apple stocks jumping in after-hours trading

Read Article

Tech companies helping keep data pirates and identity thieves at bay  

Read Article

Fast-growing Vancouver companies compete to make in-house HR software   

Read Article

UBC and SFU have churned out more than 200 spinoffs the past 30 years, but as many as a quarter haven’t survived 

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
×